Switching to Oral INVEGA® ER after 1st INVEGA TRINZA® injection

Dose Information

Graph Information

^ Back to Top


Consistent with the Prescribing Information for INVEGA TRINZA® and INVEGA®:

  • INVEGA TRINZA® is to be used only after INVEGA SUSTENNA® has been established as adequate treatment for at least four months.
  • For switching from INVEGA TRINZA® to INVEGA®, the daily dosing of INVEGA® should be started 3 months after the last INVEGA TRINZA® dose and transitioned over the next several months following the last INVEGA TRINZA® dose as described in the table below. The table provides dose conversion regimens to allow patients previously stabilized on different doses of INVEGA TRINZA® to attain similar paliperidone exposure with INVEGA®.

INVEGA TRINZA® Doses and INVEGA® Conversion Regimens Needed to Attain Similar Paliperidone Exposures

Weeks Since Last INVEGA TRINZA® Dose

3 months to 18 weeks

Longer than 18 weeks to 24 weeks

Longer than 24 weeks


Doses of INVEGA®

273 mg

3 mg

3 mg

3 mg

410 mg

3 mg

3 mg

6 mg

546 mg

3 mg

6 mg

9 mg

819 mg

6 mg

9 mg

12 mg

  • The cumulative paliperidone plasma level curve will reflect the plasma level contributions from INVEGA TRINZA® and oral INVEGA® in this scenario.

INVEGA TRINZA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+TRINZA-pi.pdf]

INVEGA® Prescribing Information

Educational Dose Illustrator for:
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA TRINZA® (paliperidone palmitate)

The Educational Dose Illustrator can be used to visualize how dosing affects paliperidone plasma concentrations following administration of:


  • the treatment of schizophrenia in adults
  • the treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants


  • the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA® for at least four months.

This resource simulates the paliperidone plasma concentrations over time resulting from different dosing scenarios that are set forth in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. The Educational Dose Illustrator is intended to be used as a resource to foster a better understanding of, and educate healthcare professionals about, the dosing recommendations provided in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. It is intended for educational purposes only.

Because the simulated patient paliperidone plasma levels shown in the dosing scenarios are based upon aggregated pharmacokinetic information from clinical studies, the simulations may not be representative of individual patient response.

Please Acknowledge

The information contained in this web site is intended for US healthcare professionals only. Privacy Policy.

Please Confirm


Thank you for visiting the Educational Dose Illustrator.

By clicking "Continue" below, you will be taken to a website where our Privacy Policy does not apply. You are solely responsible for your interactions with such websites.

We encourage you to read the Privacy Policy of every website you visit. Please view our Privacy Policy at your convenience.

Continue Cancel